| Title | Carboplatin-Pemetrexed Adjuvant Chemotherapy in Resected Non-small Cell Lung Cancer (NSCLC): A Phase II Study. | | Author(s) | Karapanagiotou EM, Boura PG, Papamichalis G, Konstantinou M, Sepsas E, Chamalakis G, Simsiris P, Gkiozos I, Syrigos KN | | Institution | Professor of Oncology in Medicine, Head, Oncology Unit, Third Department of Medicine, Athens University School of Medicine, Sotiria General Hospital, Building Z, 152 Mesogion Avenue, 115 27 Athens, Greece. knsyrigos@usa.net / ksyrigos@med.uoa.gr. | | Source | Anticancer Res 2009 Oct; 29(10):4297-301. | | Abstract | BACKGROUND: The aim of this study was to determine the progression-free survival (PFS) and toxicity associated with adjuvant administration of carboplatin and pemetrexed for completely resected patients with stage IB, II and IIIA non-small cell lung cancer (NSCLC).
PATIENTS AND METHODS: Forty-five eligible NSCLC patients received surgical resection for pathological stage IB, II or IIIA followed by postoperative adjuvant chemotherapy with carboplatin AUC5 and pemetrexed administered on days 1 and 14 on a 28-day cycle. Recombinant human granocyte colony-stimulating factor (rhG-CF) was given prophylactically.
RESULTS: The mean time to disease progression of patients was 26 months. Toxicities were generally mild to moderate and entirely manageable.
CONCLUSION: The administration of carboplatin and pemetrexed is a safe, well-tolerated and convenient regimen in the adjuvant setting of completely resected NSCLC, with efficacy similar to that reported in other regimens but less toxicity. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19846990 |
|
